<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623868</url>
  </required_header>
  <id_info>
    <org_study_id>148NF15010</org_study_id>
    <nct_id>NCT02623868</nct_id>
  </id_info>
  <brief_title>Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.</brief_title>
  <official_title>Clinical Trial to Assess the Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the pharmacokinetic/pharmacodynamic characteristics and safety/tolerability
      to CKD-519 new formulation in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, Randomized, 3-period, 6-sequence, crossover study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd/F of CKD-519</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 144h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Emax of CKD-519 CETP(Cholesteryl ester transfer protein) Activity</measure>
    <time_frame>0h, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h, 72h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of CKD-519 CETP Activity</measure>
    <time_frame>0h, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h, 72h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUEC of CKD-519 CETP Activity</measure>
    <time_frame>0h, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h, 72h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>EC50(half maximal effective concentration ) of CKD-519 CETP Activity</measure>
    <time_frame>0h, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h, 72h</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-B-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B-C-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C-A-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-C-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B-A-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C-B-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 50mg 2Tabs.</intervention_name>
    <description>after taking Standard meal, CKD-519 50mg 2Tabs. administration.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Drug A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 100mg 1Tab.</intervention_name>
    <description>after taking Standard meal, CKD-519 100mg 1Tab. administration.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Drug B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 100mg 1Cap.</intervention_name>
    <description>after taking Standard meal, CKD-519 100mg 1Cap. administration.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Drug C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 20 aged and 45 aged in healthy male adult

          2. Body weight ≥ 50kg and in the range of calculated BMI(Body Mass Index) 18~29kg/m2

          3. Subject who sign on an informed consent form willingly

          4. Necessarily he agrees that use double contraceptions and do not sperm donation until
             two months during clinical trials and after the final dosage of investigational
             products

        Exclusion Criteria:

          1. Clinically significant disease with cardiovascular, respiratory, hepatobiliary,
             nephrological, hematological, gastrointestinal, endocrine, immune, integumentary,
             neurologic, psychiatric system

          2. Have a acute disease within 28 days before the beginning of study treatment

          3. Have a disease history that can effect drug absorption, distribution, metabolism,
             excretion

          4. Have a clinically significant chronic disease

          5. Systolic blood pressure 〈100mmHg or 〉140mmHg, diastolic blood pressure〈60mmHg or
             〉90mmHg

          6. Positive for serology test (HBsAg, anti-HCV Ab, anti-HIV Ab, VDRL(Venereal Disease
             Research Laboratories))

          7. Subject treated ethical drug within 14 days before the beginning of study treatment

          8. Subject treated over-the-counter or herbal medicine within 7 days before the beginning
             of study treatment

          9. Have a clinically significant allergic disease (except for mild allergic rhinitis,
             allergic dermatitis with no drugs)

         10. Cannot take standard Meal

         11. Whole blood donation within 60 days prior to the first dosing or component blood
             donation within 20 days prior to the first dosing

         12. Blood transfusion within 30 days

         13. Taking drugs have received any other investigational drug within 90 days prior to the
             first dosing

         14. Continuously taking caffeine(〉5 cups/day), drinking alcohol(〉30g/day), smoking
             excessive cigarettes(〉10cigarettes/day)

         15. Impossible on who participants in clinical trial by investigator's decision including
             laboratory test result or another reasone(for example, noncompliance, a disobliging
             manner)

         16. Subject treated metabolizing enzyme inducers or inhibitors including barbiturates
             within 30 days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Young Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea university medical center</name>
      <address>
        <city>Seoul</city>
        <state>Sungbuk-gu</state>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>January 17, 2016</last_update_submitted>
  <last_update_submitted_qc>January 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

